TG Therapeutics, Inc. (0VGI.L)
USD 31.97
(-5.69%)
USD 31.97
(-5.69%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 12.67 Million USD | 106.22% |
| 2022 | -203.83 Million USD | 42.67% |
| 2021 | -355.55 Million USD | -24.37% |
| 2020 | -285.87 Million USD | -59.4% |
| 2019 | -179.34 Million USD | -3.38% |
| 2018 | -173.48 Million USD | -46.43% |
| 2017 | -118.47 Million USD | -51.4% |
| 2016 | -78.25 Million USD | -24.31% |
| 2015 | -62.94 Million USD | -12.85% |
| 2014 | -55.78 Million USD | -172.39% |
| 2013 | -20.47 Million USD | -13.31% |
| 2012 | -18.07 Million USD | -2018.54% |
| 2011 | -853.07 Thousand USD | -236.79% |
| 2010 | 623.64 Thousand USD | 122.33% |
| 2009 | -2.79 Million USD | 34.57% |
| 2008 | -4.26 Million USD | 64.52% |
| 2007 | -12.03 Million USD | -24.11% |
| 2006 | -9.69 Million USD | 49.35% |
| 2005 | -19.14 Million USD | -224.64% |
| 2004 | -5.89 Million USD | 1.09% |
| 2003 | -5.96 Million USD | -285.34% |
| 2002 | -1.54 Million USD | 10.84% |
| 2001 | -1.73 Million USD | 70.1% |
| 2000 | -5.8 Million USD | -141.77% |
| 1999 | -2.4 Million USD | 14.29% |
| 1998 | -2.8 Million USD | 46.15% |
| 1997 | -5.2 Million USD | -44.44% |
| 1996 | -3.6 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -10.7 Million USD | 25.73% |
| 2024 Q2 | 6.87 Million USD | 164.25% |
| 2024 Q3 | 3.88 Million USD | -43.6% |
| 2023 Q2 | -47.61 Million USD | -23.25% |
| 2023 Q4 | -14.41 Million USD | -112.65% |
| 2023 Q1 | -38.62 Million USD | 28.37% |
| 2023 FY | 12.67 Million USD | 106.22% |
| 2023 Q3 | 113.93 Million USD | 339.3% |
| 2022 Q3 | -36.67 Million USD | 12.85% |
| 2022 Q4 | -53.92 Million USD | -47.04% |
| 2022 Q2 | -42.07 Million USD | 40.86% |
| 2022 FY | -203.83 Million USD | 42.67% |
| 2022 Q1 | -71.15 Million USD | 23.77% |
| 2021 Q1 | -90.62 Million USD | -2.73% |
| 2021 FY | -355.55 Million USD | -24.37% |
| 2021 Q2 | -78.49 Million USD | 13.39% |
| 2021 Q3 | -85.63 Million USD | -9.1% |
| 2021 Q4 | -93.33 Million USD | -8.99% |
| 2020 Q4 | -88.21 Million USD | -1.21% |
| 2020 Q3 | -87.16 Million USD | -64.82% |
| 2020 Q1 | -51.11 Million USD | -29.18% |
| 2020 FY | -285.87 Million USD | -59.4% |
| 2020 Q2 | -52.88 Million USD | -3.46% |
| 2019 FY | -179.34 Million USD | -3.38% |
| 2019 Q4 | -39.57 Million USD | 36.1% |
| 2019 Q1 | -35.15 Million USD | 34.73% |
| 2019 Q2 | -36.21 Million USD | -3.01% |
| 2019 Q3 | -61.93 Million USD | -71.02% |
| 2018 Q3 | -33.95 Million USD | 23.09% |
| 2018 Q4 | -53.86 Million USD | -58.64% |
| 2018 FY | -173.48 Million USD | -46.43% |
| 2018 Q1 | -41.52 Million USD | -34.57% |
| 2018 Q2 | -44.14 Million USD | -6.29% |
| 2017 Q3 | -31.53 Million USD | -11.22% |
| 2017 FY | -118.47 Million USD | -51.4% |
| 2017 Q4 | -30.85 Million USD | 2.14% |
| 2017 Q1 | -27.72 Million USD | -17.12% |
| 2017 Q2 | -28.35 Million USD | -2.26% |
| 2016 FY | -78.25 Million USD | -24.31% |
| 2016 Q1 | -13.84 Million USD | 21.37% |
| 2016 Q2 | -15.89 Million USD | -14.81% |
| 2016 Q3 | -24.83 Million USD | -56.18% |
| 2016 Q4 | -23.67 Million USD | 4.66% |
| 2015 Q4 | -17.61 Million USD | -28.97% |
| 2015 Q1 | -14.57 Million USD | 22.44% |
| 2015 Q2 | -17.1 Million USD | -17.32% |
| 2015 Q3 | -13.65 Million USD | 20.16% |
| 2015 FY | -62.94 Million USD | -12.85% |
| 2014 Q4 | -18.79 Million USD | -7.71% |
| 2014 FY | -55.78 Million USD | -172.39% |
| 2014 Q3 | -17.45 Million USD | -45.59% |
| 2014 Q2 | -11.98 Million USD | -58.82% |
| 2014 Q1 | -7.54 Million USD | -33.25% |
| 2013 Q2 | -6.58 Million USD | -79.24% |
| 2013 Q1 | -3.67 Million USD | -6.18% |
| 2013 FY | -20.47 Million USD | -13.31% |
| 2013 Q4 | -5.66 Million USD | -24.31% |
| 2013 Q3 | -4.55 Million USD | 30.8% |
| 2012 Q3 | -2.46 Million USD | -29.96% |
| 2012 Q4 | -3.45 Million USD | -40.51% |
| 2012 FY | -18.07 Million USD | -2018.54% |
| 2012 Q1 | -10.25 Million USD | -790.92% |
| 2012 Q2 | -1.89 Million USD | 81.53% |
| 2011 Q2 | -2.98 Million USD | -177.82% |
| 2011 Q3 | -551.73 Thousand USD | 81.5% |
| 2011 FY | -853.07 Thousand USD | -236.79% |
| 2011 Q4 | -1.15 Million USD | -108.65% |
| 2011 Q1 | 3.83 Million USD | 949.3% |
| 2010 Q1 | -1.63 Million USD | -632.65% |
| 2010 Q2 | 1.85 Million USD | 213.3% |
| 2010 Q3 | 41.24 Thousand USD | -97.77% |
| 2010 FY | 623.64 Thousand USD | 122.33% |
| 2010 Q4 | 365.23 Thousand USD | 785.47% |
| 2009 Q2 | -1.39 Million USD | -82.77% |
| 2009 Q3 | -416.08 Thousand USD | 70.12% |
| 2009 FY | -2.79 Million USD | 34.57% |
| 2009 Q4 | -222.91 Thousand USD | 46.43% |
| 2009 Q1 | -761.84 Thousand USD | -699.79% |
| 2008 Q3 | -1.39 Million USD | 1.96% |
| 2008 Q4 | 127.01 Thousand USD | 109.11% |
| 2008 FY | -4.26 Million USD | 64.52% |
| 2008 Q1 | -1.55 Million USD | 18.1% |
| 2008 Q2 | -1.42 Million USD | 8.8% |
| 2007 Q1 | -2.56 Million USD | 18.03% |
| 2007 Q4 | -1.9 Million USD | 28.67% |
| 2007 Q3 | -2.66 Million USD | 45.46% |
| 2007 Q2 | -4.89 Million USD | -90.87% |
| 2007 FY | -12.03 Million USD | -24.11% |
| 2006 Q1 | -2.81 Million USD | -10.77% |
| 2006 Q2 | -2.27 Million USD | 19.32% |
| 2006 Q4 | -3.12 Million USD | -64.88% |
| 2006 Q3 | -1.89 Million USD | 16.45% |
| 2006 FY | -9.69 Million USD | 49.35% |
| 2005 Q4 | -2.54 Million USD | -40.21% |
| 2005 Q2 | -13.36 Million USD | -836.91% |
| 2005 FY | -19.14 Million USD | -224.64% |
| 2005 Q1 | -1.42 Million USD | 18.28% |
| 2005 Q3 | -1.81 Million USD | 86.43% |
| 2004 Q3 | -2.19 Million USD | -154.65% |
| 2004 Q1 | -1.09 Million USD | 27.44% |
| 2004 Q4 | -1.74 Million USD | 20.47% |
| 2004 FY | -5.89 Million USD | 1.09% |
| 2004 Q2 | -861.6 Thousand USD | 21.34% |
| 2003 FY | -5.96 Million USD | -285.34% |
| 2003 Q1 | -421.94 Thousand USD | -13.83% |
| 2003 Q2 | -776.31 Thousand USD | -83.99% |
| 2003 Q3 | -3.25 Million USD | -319.03% |
| 2003 Q4 | -1.5 Million USD | 53.59% |
| 2002 Q1 | -624.07 Thousand USD | -10.43% |
| 2002 Q3 | -586.41 Thousand USD | -1812.96% |
| 2002 FY | -1.54 Million USD | 10.84% |
| 2002 Q4 | -370.68 Thousand USD | 36.79% |
| 2002 Q2 | 34.23 Thousand USD | 105.49% |
| 2001 Q4 | -565.15 Thousand USD | 23.17% |
| 2001 FY | -1.73 Million USD | 70.1% |
| 2001 Q1 | 1.68 Million USD | 562.86% |
| 2001 Q2 | -2.12 Million USD | -225.74% |
| 2001 Q3 | -735.56 Thousand USD | 65.32% |
| 2000 Q3 | -972.42 Thousand USD | 68.5% |
| 2000 Q1 | -1.37 Million USD | -129.71% |
| 2000 FY | -5.8 Million USD | -141.77% |
| 2000 Q2 | -3.08 Million USD | -124.01% |
| 2000 Q4 | -364.45 Thousand USD | 62.52% |
| 1999 FY | -2.4 Million USD | 14.29% |
| 1999 Q4 | -600 Thousand USD | -100.0% |
| 1999 Q3 | -300 Thousand USD | 50.0% |
| 1999 Q2 | -600 Thousand USD | 33.33% |
| 1999 Q1 | -900 Thousand USD | 30.77% |
| 1998 FY | -2.8 Million USD | 46.15% |
| 1998 Q2 | 1 Million USD | 176.92% |
| 1998 Q3 | -1.2 Million USD | -220.0% |
| 1998 Q4 | -1.3 Million USD | -8.33% |
| 1998 Q1 | -1.3 Million USD | 13.33% |
| 1997 Q3 | -1 Million USD | 44.44% |
| 1997 Q4 | -1.5 Million USD | -50.0% |
| 1997 FY | -5.2 Million USD | -44.44% |
| 1997 Q1 | -900 Thousand USD | 10.0% |
| 1997 Q2 | -1.8 Million USD | -100.0% |
| 1996 Q3 | -1.1 Million USD | -37.5% |
| 1996 Q4 | -1 Million USD | 9.09% |
| 1996 FY | -3.6 Million USD | 0.0% |
| 1996 Q1 | -800 Thousand USD | 0.0% |
| 1996 Q2 | -800 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 100.147% |
| uniQure N.V. | -308.47 Million USD | 104.108% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 114.322% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 103.599% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 108.36% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 104.589% |
| bluebird bio, Inc. | -211.91 Million USD | 105.98% |
| Blueprint Medicines Corporation | -506.98 Million USD | 102.499% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 110.692% |
| Imunon, Inc. | -19.51 Million USD | 164.935% |
| Adicet Bio, Inc. | -142.65 Million USD | 108.883% |
| Dynavax Technologies Corporation | -6.38 Million USD | 298.341% |
| Editas Medicine, Inc. | -153.21 Million USD | 108.271% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 111.462% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 102.854% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 99.067% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 98.393% |
| Myriad Genetics, Inc. | -112 Million USD | 111.314% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 94.925% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 102.364% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | -862.918% |
| Verastem, Inc. | -87.36 Million USD | 114.504% |
| Waters Corporation | 642.23 Million USD | 98.027% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 99.65% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 99.789% |
| Biogen Inc. | 1.16 Billion USD | 98.909% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 114.753% |
| Perrigo Company plc | -12.7 Million USD | 199.78% |
| Unity Biotechnology, Inc. | -39.86 Million USD | 131.791% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 106.056% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 123.385% |
| Geron Corporation | -184.12 Million USD | 106.882% |
| Illumina, Inc. | -1.16 Billion USD | 101.091% |
| Homology Medicines, Inc. | -53.74 Million USD | 123.579% |
| Nektar Therapeutics | -276.05 Million USD | 104.59% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 128.41% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 92.441% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 104.915% |
| Evolus, Inc. | -61.68 Million USD | 120.543% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 99.679% |
| FibroGen, Inc. | -284.23 Million USD | 104.458% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 98.978% |
| OPKO Health, Inc. | -188.86 Million USD | 106.71% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 102.878% |
| Exelixis, Inc. | 207.76 Million USD | 93.901% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 126.675% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 102.633% |
| Zoetis Inc. | 2.34 Billion USD | 99.459% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 105.297% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 130.029% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 103.46% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 88.061% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 95.5% |
| Insmed Incorporated | -749.56 Million USD | 101.691% |
| Incyte Corporation | 597.59 Million USD | 97.88% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 101.666% |